SCN9A and prostate carcinoma: Similarly, in prostate cancer models such as Mat-LyLu-Copenhagen rats and PC3-BALB/c mice, interventions including gavage ranolazine and subcutaneous injection of tetrodotoxin have shown promise in altering cancer progression by targeting Nav1.7 or pan-α-subunits, respectively [54, 78–80].